Patent Expiry

Patent/Exclusivity Expiry: RYTELO

Drug
RYTELO

Other upcoming events for GERN

Phase 3 ReadoutPhase 3 Topline: A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therap

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Patent/Exclusivity Expiry: RYTELO — GERN Patent Expiry | BioSniper